Envestnet Asset Management Inc Bei Gene, Ltd. Transaction History

Envestnet Asset Management Inc

$302 Billion
Q3 2024

A detailed history of Envestnet Asset Management Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 56,582 shares of BGNE stock, worth $12.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,582

Previous 63,140 10.39%

Holding current value

$12.8 Million

Previous $9.01 Million 41.02%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$143.93 - $224.51 $943,892 - $1.47 Million	-6,558 Reduced 10.39%	56,582 $12.7 Million
Q2 2024 Aug 08, 2024	SELL	$129.52 - $174.32 $213,189 - $286,930	-1,646 Reduced 2.54%	63,140 $9.01 Million
Q1 2024 May 13, 2024	BUY	$141.8 - $181.47 $2.19 Million - $2.8 Million	15,421 Added 31.24%	64,786 $10.1 Million
Q4 2023 Feb 13, 2024	BUY	$158.67 - $201.58 $425,711 - $540,839	2,683 Added 5.75%	49,365 $8.9 Million
Q3 2023 Nov 13, 2023	BUY	$179.87 - $225.13 $2.93 Million - $3.67 Million	16,295 Added 53.62%	46,682 $8.4 Million
Q2 2023 Aug 04, 2023	SELL	$178.3 - $266.78 $293,660 - $439,386	-1,647 Reduced 5.14%	30,387 $5.42 Million
Q1 2023 May 11, 2023	BUY	$215.53 - $274.5 $700,472 - $892,125	3,250 Added 11.29%	32,034 $6.9 Million
Q4 2022 Feb 07, 2023	BUY	$125.51 - $229.3 $508,315 - $928,665	4,050 Added 16.37%	28,784 $6.33 Million
Q3 2022 Nov 10, 2022	SELL	$131.8 - $202.24 $12,257 - $18,808	-93 Reduced 0.37%	24,734 $3.34 Million
Q2 2022 Aug 03, 2022	BUY	$121.11 - $216.05 $92,528 - $165,062	764 Added 3.17%	24,827 $4.02 Million
Q1 2022 May 04, 2022	BUY	$146.52 - $269.56 $218,607 - $402,183	1,492 Added 6.61%	24,063 $4.54 Million
Q4 2021 Feb 04, 2022	BUY	$248.56 - $389.34 $132,482 - $207,518	533 Added 2.42%	22,571 $6.12 Million
Q3 2021 Oct 07, 2021	BUY	$249.6 - $403.14 $518,918 - $838,128	2,079 Added 10.42%	22,038 $8 Million
Q2 2021 Aug 04, 2021	BUY	$292.75 - $367.01 $753,831 - $945,050	2,575 Added 14.81%	19,959 $6.85 Million
Q1 2021 May 04, 2021	BUY	$260.64 - $382.12 $1.14 Million - $1.67 Million	4,358 Added 33.46%	17,384 $6.05 Million
Q4 2020 Feb 02, 2021	BUY	$221.31 - $316.61 $508,349 - $727,253	2,297 Added 21.41%	13,026 $3.37 Million
Q3 2020 Oct 09, 2020	BUY	$189.18 - $286.44 $373,819 - $566,005	1,976 Added 22.58%	10,729 $3.07 Million
Q2 2020 Jul 08, 2020	BUY	$123.9 - $195.41 $74,463 - $117,441	601 Added 7.37%	8,753 $1.65 Million
Q1 2020 Apr 23, 2020	SELL	$121.84 - $173.19 $34,846 - $49,532	-286 Reduced 3.39%	8,152 $1 Million
Q4 2019 Feb 11, 2020	BUY	$115.78 - $208.34 $172,512 - $310,426	1,490 Added 21.45%	8,438 $1.4 Million
Q3 2019 Oct 17, 2019	SELL	$120.61 - $148.29 $6,151 - $7,562	-51 Reduced 0.73%	6,948 $851,000
Q2 2019 Aug 02, 2019	BUY	$113.99 - $146.86 $47,533 - $61,240	417 Added 6.34%	6,999 $868,000
Q1 2019 May 10, 2019	BUY	$122.82 - $151.83 $190,493 - $235,488	1,551 Added 30.83%	6,582 $869,000
Q4 2018 Feb 13, 2019	BUY	$107.01 - $175.15 $538,367 - $881,179	5,031 New	5,031 $706,000

Others Institutions Holding BGNE

# of Institutions

253

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.

Account

Envestnet Asset Management Inc Bei Gene, Ltd. Transaction History